IP Verse

Treatment Of Amd Using Aav Sflt-1 - EP2849802

The patent EP2849802 was granted to Avalanche Australia on Dec 20, 2023. The application was originally filed on May 7, 2013 under application number EP13791695A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP2849802

AVALANCHE AUSTRALIA
Application Number
EP13791695A
Filing Date
May 7, 2013
Status
Granted And Under Opposition
Nov 17, 2023
Grant Date
Dec 20, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

STRAWMANSep 19, 2024CMS CAMERON MCKENNA NABARRO OLSWANGADMISSIBLE

Patent Citations (29) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS20070297958-
DESCRIPTIONUS2010008170
DESCRIPTIONUS4522811
DESCRIPTIONUS5712380
DESCRIPTIONUS5861484
DESCRIPTIONUS7071159
DESCRIPTIONUS7635474
DESCRIPTIONWO9208796
DESCRIPTIONWO9428143
DESCRIPTIONWO9522618
INTERNATIONAL-SEARCH-REPORTUS2002194630
INTERNATIONAL-SEARCH-REPORTUS2006193830
INTERNATIONAL-SEARCH-REPORTUS2006234347
INTERNATIONAL-SEARCH-REPORTUS2010272719
INTERNATIONAL-SEARCH-REPORTWO2004079332
INTERNATIONAL-SEARCH-REPORTWO2008142124
INTERNATIONAL-SEARCH-REPORTWO2009073551
INTERNATIONAL-SEARCH-REPORTWO2011126808
INTERNATIONAL-SEARCH-REPORTWO2011137344
OPPOSITIONUS2002194630
OPPOSITIONUS2006193830
OPPOSITIONUS2006234347
OPPOSITIONUS2010272719
OPPOSITIONWO2004079332
OPPOSITIONWO2006031689
OPPOSITIONWO2008142124
OPPOSITIONWO2009073551
OPPOSITIONWO2011126808
OPPOSITIONWO2011137344

Non-Patent Literature (NPL) Citations (38) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- LAI Y K Y ET AL, "Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy", GENE THERAPY, NATURE PUBLISHING GROUP, GB, (20020601), vol. 9, no. 12, doi:10.1038/SJ.GT.3301695, ISSN 0969-7128, pages 804 - 813, XP002487065
OPPOSITION- Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION - EYLEA™ (aflibercept) Injection", Regeneron Pharmaceuticals, Inc., (20111101), pages 1 - 15, XP055895379-
OPPOSITION- Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION- LUCENTIS™ (ranibizumab injection)", Genentech, Inc., (20060101), pages 1 - 7, Genentech, Inc.,, URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/125156lbl.pdf, (20191114), XP055642530-
OPPOSITION- Anonymous Melissa, Roxanne Croze; Laura Kovacs; Maria Osuna; Domokos Lauko; Ted Sullivan; Caralee Schaefer; Devi Khoday; Joseph Vacca; An Song; David Kirn, "Preclinical characterization of 4D-175, a novel AAV-based investigational intravitreal gene therapy for geographic atrophy", Investigative Ophthalmology & Visual Science, Association for Research in Vision and Ophthalmology, US, US , (20240601), vol. 65, no. 7, ISSN 0146-0404, page 6164, XP093225161-
OPPOSITION- Anonymous, "Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration - Full Text View - ClinicalTrials.gov", (20111216), URL: https://clinicaltrials.gov/show/NCT01494805, (20150318), XP055177576-
OPPOSITION- Beckman Richard L, "ADVM-022 for Neovascular AMD", Gene Therapy for Ophthalmic Disorders Meeting; September 13-16, 2022 Boston, MA, USA, (20220915), pages 1 - 48, XP093225658-
OPPOSITION- DAVIS-SMYTH T., ET AL., "THE SECOND IMMUNOGLOBULIN-LIKE DOMAIN OF THE VEGF TYROSINE KINASE RECEPTOR FLT-1 DETERMINES LIGAND BINDING AND MAY INITIATE A SIGNAL TRANSDUCTION CASCADE.", The EMBO journal / European Molecular Biology Organization, IRL Press, Oxford, Oxford , (19960916), vol. 15., no. 18., ISSN 0261-4189, pages 4919 - 4927., XP000611912-
OPPOSITION- Genzyme, A Sanofi Company, "NCT01024998 | Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)", ClinicalTrials.gov, NLM, (20120413), pages 1 - 13, ClinicalTrials.gov, URL: https://clinicaltrials.gov/study/NCT01024998?term=NCT01024998&rank=1&tab=history&a=10#version-content-panel, XP093225148-
OPPOSITION- Khanani Arshad M, "First Interim Results (24 weeks) for the Randomized Phase 2 Dose Expansion Stage of the PRISM Clinical Trial of 4D-150 in High Need Patients with nAMD", Angiogenesis, Exudation, and Degeneration 2024; Online, Miami, FL, USA, University of Miami Leonard M. Miller School of Medicine, (20240203), pages 1 - 15, XP093225636-
OPPOSITION- Wykoff Charles C, Harry Flynn, Jr.; Dennis P. Han, "Perioperative Management of Patients with Reported Povidone-Iodine or Penicillin / Cephalosporin Allergies", Investigative Ophthalmology & Visual Science, Association for Research in Vision and Ophthalmology, US, US , (20110401), vol. 52, no. 14, ISSN 0146-0404, page 6416, XP093224969-
OPPOSITION- Lalwani, G.A. ; Rosenfeld, P.J. ; Fung, A.E. ; Dubovy, S.R. ; Michels, S. ; Feuer, W. ; Davis, J.L. ; Flynn, H.W. ; Esquiabro, M., "A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study", American Journal of Ophthalmology, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL , (20090701), vol. 148, no. 1, doi:10.1016/j.ajo.2009.01.024, ISSN 0002-9394, pages 43 - 58.e1, XP026210397
OPPOSITION- Krohne Tim U., Liu Zengping, Holz Frank G., Meyer Carsten H., "Intraocular Pharmacokinetics of Ranibizumab Following a Single Intravitreal Injection in Humans", American Journal of Ophthalmology, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL , (20121001), vol. 154, no. 4, doi:10.1016/j.ajo.2012.03.047, ISSN 0002-9394, pages 682 - 686.e2, XP093225044
OPPOSITION- Lai, C.M. Shen, W.Y. Brankov, M. Lai, Y.K.Y. Barnett, N.L. Lee, S.Y. Yeo, I.Y.S. Mathur, R. Ho, J.E.S. Pineda, P. Barathi, A. Ang, C.L. Constable, I.J. Rakoczy, E.P., "Long-term Evaluation of AAV-Mediated sFlt-1 Gene Therapy for Ocular Neovascularization in Mice and Monkeys", Molecular Therapy, Elsevier Inc., US, US , (20051001), vol. 12, no. 4, doi:10.1016/j.ymthe.2005.04.022, ISSN 1525-0016, pages 659 - 668, XP005078445
OPPOSITION- Sarra G.M, Stephens C, Schlichtenbrede F.C, Bainbridge J.W.B, Thrasher A.J, Luthert P.J, Ali R.R, "Kinetics of transgene expression in mouse retina following sub-retinal injection of recombinant adeno-associated virus", Vision Research, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20020201), vol. 42, no. 4, doi:10.1016/S0042-6989(01)00230-9, ISSN 0042-6989, pages 541 - 549, XP093224978
OPPOSITION- Rakoczy Elizabeth P; Lai Chooi-May; Magno Aaron L; Wikstrom Matthew E; French Martyn A; Pierce Cora M; Schwartz Steven D; Blumenkranz Mark S; Chalberg Thomas W; Degli-Esposti Mariapia A; Constable Ian J, "Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial", The Lancet, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20150930), vol. 386, no. 10011, doi:10.1016/S0140-6736(15)00345-1, ISSN 0140-6736, pages 2395 - 2403, XP029344231
OPPOSITION- WEBER MICHEL ET AL, "Recombinant adeno-associated virus serotype 4 mediates unique and exclusive long-term transduction of retinal pigmented epithelium in rat, dog, and nonhuman primate after subretinal delivery.", Molecular Therapy, Elsevier Inc., US, US , (20030601), vol. 7, no. 6, doi:10.1016/S1525-0016(03)00098-4, ISSN 1525-0016, pages 774 - 781, XP002295354
OPPOSITION- Pechan P; Rubin H; Lukason M; Ardinger J; DuFresne E; Hauswirth W W; Wadsworth S C; Scaria A, "Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization", Gene Therapy, Nature Publishing Group, London, GB, GB , (20080717), vol. 16, no. 1, doi:10.1038/gt.2008.115, ISSN 0969-7128, pages 10 - 16, XP037771458
OPPOSITION- Lai C-M; Estcourt M J; Himbeck R P; Lee S-Y; Yew-San Yeo I; Luu C; Loh B K; Lee M W; Barathi A; Villano J; Ang C-L; van der Most R G; Constable I J; Dismuke D; Samulski R J; Degli-Esposti M A; Rakoczy E P, "Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates", Gene Therapy, Nature Publishing Group, London, GB, GB , (20111110), vol. 19, no. 10, doi:10.1038/gt.2011.169, ISSN 0969-7128, pages 999 - 1009, XP037771901
OPPOSITION- Carmela Zincarelli, Stephen Soltys, Giuseppe Rengo, Joseph E Rabinowitz, "Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection", Molecular Therapy, Elsevier Inc., US, US , (20080601), vol. 16, no. 6, doi:10.1038/mt.2008.76, ISSN 1525-0016, pages 1073 - 1080, XP055338752
OPPOSITION- Michael Lukason, Elizabeth Dufresne, Hillard Rubin, Peter Pechan, Qiuhong Li, Ivana Kim, Szilard Kiss, Christina Flaxel, Margaret Collins, Joan Miller, William Hauswirth, Timothy Maclachlan, Samuel Wadsworth, Abraham Scaria, "Inhibition of Choroidal Neovascularization in a Nonhuman Primate Model by Intravitreal Administration of an AAV2 Vector Expressing a Novel Anti-VEGF Molecule", Molecular Therapy, No longer published by Elsevier, (20110201), vol. 19, no. 2, doi:10.1038/mt.2010.230, ISSN 15250016, pages 260 - 265, XP055188907
OPPOSITION- Timothy K Maclachlan, Michael Lukason, Margaret Collins, Robert Munger, Elisabete Isenberger, Cindy Rogers, Shana Malatos, Elizabeth Dufresne, James Morris, Roberto Calcedo, Gabor Veres, Abraham Scaria, Laura Andrews, Samuel Wadsworth, "Preclinical Safety Evaluation of AAV2-sFLT01— A Gene Therapy for Age-related Macular Degeneration", Molecular Therapy, No longer published by Elsevier, (20110201), vol. 19, no. 2, doi:10.1038/mt.2010.258, ISSN 15250016, pages 326 - 334, XP055136302
OPPOSITION- Lai YKY; Shen WY; Brankov M; Lai CM; Constable IJ; Rakoczy PE, "Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy", Gene Therapy, Nature Publishing Group, London, GB, GB , (20020601), vol. 9, no. 12, doi:10.1038/sj.gt.3301695, ISSN 0969-7128, pages 804 - 813, XP037772204
OPPOSITION- J. Timothy Stout, Peter J. Francis, "Surgical Approaches to Gene and Stem Cell Therapy for Retinal Disease", Human Gene Therapy, Mary Ann Liebert, (20110501), vol. 22, no. 5, doi:10.1089/hum.2011.060, ISSN 10430342, pages 531 - 535, XP055177073
OPPOSITION- Aysha Salam; Raeba Mathew; Sobha Sivaprasad, "Treatment of proliferative diabetic retinopathy with anti‐VEGF agents", Acta Ophthalmologica: the ophthalmological journal of the Nordic countries, Wiley-Blackwell Munksgaard, Denmark, Denmark , (20110205), vol. 89, no. 5, doi:10.1111/j.1755-3768.2010.02079.x, ISSN 1755-375X, pages 405 - 411, XP072391603
OPPOSITION- S. Daya, Berns K. I., "Gene Therapy Using Adeno-Associated Virus Vectors", Clinical microbiology reviews, American Society for Microbiology (ASM), (20081001), vol. 21, no. 4, doi:10.1128/CMR.00008-08, ISSN 08938512, pages 583 - 593, XP055060791
OPPOSITION- C.-M. Lai, M. J. Estcourt, M. Wikstrom, R. P. Himbeck, N. L. Barnett, M. Brankov, L. B. G. Tee, S. A. Dunlop, M. A. Degli-Esposti, E. P. Rakoczy, "rAAV.sFlt-1 Gene Therapy Achieves Lasting Reversal of Retinal Neovascularization in the Absence of a Strong Immune Response to the Viral Vector", Investigative Ophthalmology & Visual Science, ¬Association for Research in Vision and Ophthalmology, etc.|, (20090901), vol. 50, no. 9, doi:10.1167/iovs.08-3253, ISSN 01460404, pages 4279 - 4287, XP055177071
OPPOSITION- Lee Suhwan, Kang Im Kyeung, Kim Ji Hyun, Jung Bok Kyoung, Park Keerang, Chang Heesoon, Lee Joo Yong, Lee Heuiran, "Relationship Between Neutralizing Antibodies Against Adeno-Associated Virus in the Vitreous and Serum: Effects on Retinal Gene Therapy", Translational Vision Science & Technology, Association for Research in Vision and Ophthalmology, US, US , (20190301), vol. 8, no. 2, doi:10.1167/tvst.8.2.14, ISSN 2164-2591, pages 14 - 9, XP093225049
OPPOSITION- Maynard Sharon E, Venkatesha Shivalingappa, Thadhani Ravi, Karumanchi S Ananth, "Soluble Fms-like Tyrosine Kinase 1 and Endothelial Dysfunction in the Pathogenesis of Preeclampsia", Pediatric Research, Lippincott Williams & Wilkins, New York, US, US , (20050501), vol. 57, no. 5 Part 2, doi:10.1203/01.PDR.0000159567.85157.B7, ISSN 0031-3998, pages 1R - 7R, XP093224975
OPPOSITION- Eric Chen, Benz, Fish, Brown, Wong, Kim, Major, "Use of nepafenac (Nevanac®) in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections", Clinical Ophthalmology, doi:10.2147/OPTH.S14092, page 1249, XP055177069
OPPOSITION- Au Hau Kiu Edna, Isalan Mark, Mielcarek Michal, "Gene Therapy Advances: A Meta-Analysis of AAV Usage in Clinical Settings", Frontiers in Medicine, Frontiers Media S.A., vol. 8, doi:10.3389/fmed.2021.809118, ISSN 2296-858X, pages 809118 - 14, XP093044395
OPPOSITION- Irigoyen Cristina, Amenabar Alonso Asier, Sanchez-Molina Jorge, Rodríguez-Hidalgo María, Lara-López Araceli, Ruiz-Ederra Javier, "Subretinal Injection Techniques for Retinal Disease: A Review", Journal of Clinical Medicine, Multidisciplinary Digital Publishing Institute (MDPI), CH, CH , (20220812), vol. 11, no. 16, doi:10.3390/jcm11164717, ISSN 2077-0383, page 4717, XP093184231
OPPOSITION- García-Quintanilla Laura, Luaces-Rodríguez Andrea, Gil-Martínez María, Mondelo-García Cristina, Maroñas Olalla, Mangas-Sanjuan Víctor, González-Barcia Miguel, Zarra-Ferro Irene, Aguiar Pablo, Otero-Espinar Francisco J., Fernández-Ferreiro Anxo, "Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration", Pharmaceutics, MDPI AG, Switzerland, Switzerland, (20190801), vol. 11, no. 8, doi:10.3390/pharmaceutics11080365, ISSN 1999-4923, pages 365 - 22, XP093225037
OPPOSITION- Bastola Prabhakar, Song Liujiang, Gilger Brian C., Hirsch Matthew L., "Adeno-Associated Virus Mediated Gene Therapy for Corneal Diseases", Pharmaceutics, vol. 12, no. 8, doi:10.3390/pharmaceutics12080767, page 767, XP055883004
OPPOSITION- Bower Jacquelyn, Song Zhenwei, Song Liujiang, "Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models", Journal of Visualized Experiments, JoVE, US, US , (20220101), no. 181, doi:10.3791/63532, ISSN 1940-087X, pages 1 - 14, XP009558309
SEARCH- US National Health Institute, "Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration", (20111216), Clinical Trials, URL: https://clinicaltrials.gov/archive/NCT01494805/2011_12_16, (20151204), XP002751808 [X] 9-15 * the whole document * [Y] 1-15-
SEARCH- US National Institute of Health, "Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)", (20120413), Clinical Trials, URL: https://clinicaltrials.gov/archive/NCT01024998/2012_04_13, (20151204), XP002751809 [X] 9-15 * the whole document * [Y] 1-15-
SEARCH- MICHAEL LUKASON ET AL, "Inhibition of Choroidal Neovascularization in a Nonhuman Primate Model by Intravitreal Administration of an AAV2 Vector Expressing a Novel Anti-VEGF Molecule", MOLECULAR THERAPY, (20101026), vol. 19, no. 2, doi:10.1038/mt.2010.230, ISSN 1525-0016, pages 260 - 265, XP055188907 [X] 9-15 * abstract * [Y] 1-15
SEARCH- TIMOTHY K MACLACHLAN ET AL, "Preclinical Safety Evaluation of AAV2-sFLT01- A Gene Therapy for Age-related Macular Degeneration", MOLECULAR THERAPY, (20101130), vol. 19, no. 2, doi:10.1038/mt.2010.258, ISSN 1525-0016, pages 326 - 334, XP055136302 [X] 9-15 * abstract * [Y] 1-15

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents